“
TL;DR
Untreated MSCs alone showed no significant benefit over diabetic controls.
Biomedicines · 9 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
Untreated MSCs alone showed no significant benefit over diabetic controls.
DR was confirmed at 10 weeks post-STZ injection by reduced ERG amplitudes and retinal thinning. Treatment consisted of two subconjunctival injections at 8-day intervals, with evaluation over a maximum of 7 weeks. The DR-MSC-S group demonstrated significant improvements in both flash b-wave and flicker ERG amplitudes compared to the DR group, along with greater total retinal thickness, inner nuclear layer thickness, and photoreceptor layer thickness. The DR-MSC group did not differ significantly from the DR group in flash b-wave amplitude or histological outcomes, attributed to reduced MSC survival in the hyperglycemic environment. Subconjunctival administration was effective with minimal systemic impact on body weight or blood glucose. Limitations include the short evaluation period and absence of dose-comparison or single versus repeated administration analyses.